Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The stock is down 11% in just the past three months.

Walgreens Boots Alliance Is Near Its 52-Week Low: Is Now the Time to Buy?

Walgreens (WBA) reported earnings 30 days ago. What's next for the stock?

Walgreens (WBA) Down 2.2% Since Last Earnings Report: Can It Rebound?

Aetna

Anthem

Cigna

CVS Health

Express Scripts Holding

Humana

WellCare Health Plans

The U.S. health insurance market, roiled by transformative deals in recent years, will likely face a lull in major deal activity in 2020 while firms await critical federal election outcomes.

Feel The Bern: Presidential Race Throws Cold Water On Health Insurance Mega-Mergers

Walgreens Boots Alliance promoted Richard Ashworth to become President of Walgreens following an operations role he had with the global pharmacy chain.

Walgreens Shuffles Senior Management To Boost U.S. Pharmacies

JPMorgan Chase & Co

Rite Aid

Herbalife

Pharmacies & Drug Stores Industry Outlook: Prospects Mixed

Walgreens Boots Alliance Inc. WBA, +0.22% said Monday it has expanded its partnership with India-based technology consultant Tata Consultancy Services 532540, -2.86% to accelerate its digital transformation.

Walgreens to expand IT partnership with India's Tata Consultancy to speed up digital transformation

Fast-growing VillageMd said it is acquiring an Arizona primary care practice for an undisclosed sum as the privately held venture expands into new markets across the U. S.Chicago-based VillageMD, which includes Walgreens Boots Alliance as a partner in the Houston area, said it has agreed to acqui.

Walgreens Primary Care Partner VillageMD Gobbling More Doctor Practices

Walgreens Boots Alliance Inc. (NASDAQ:WBA) offers good value for money following its 29% decline over the past year.

Why Walgreens Boots Alliance Has Upside

Walgreens Boots Alliance top executive told shareholders the company’s cost management plan is freeing up money to invest in myriad partnerships and growth for the future.

Walgreens CEO To Shareholders: We’re Saving To Invest In Growth

With The Growth Thesis Gone, Walgreens Is Now Just A Dividend Play

Novartis

The sector is a safe bet for long-term growth, but which health-care stocks stand to gain the most? Here are three picks to consider today.

3 Great Healthcare Stocks to Buy Right Now

Walgreens Boots Alliance is expected to face questions this week about a potential effort to take the global pharmacy chain private from shareholders when they hold their annual stockholders meeting.

Shareholders May Press Walgreens On Buyout At Annual Meeting

Walgreens: Limited Upside, But Good Valuation

Three factors are putting a damper on this pharmacy retailer.

Can Walgreens Continue to Grow in 2020?

Walgreens Boots Alliance total expenses have increased gradually from around $99 billion in fiscal 2015 to about $133 billion in fiscal 2019. As a percentage of revenues, expenses have grown, going from 95.9% to 97.1% over the same period.

How Does Walgreens Spend Its Money?

Walgreens Boots Alliance said it is working on more ways to partner with physicians and hinted at some new deals with doctors in the works for 2020.

Walgreens: Look For More Doctor Partnerships In 2020

Covis Pharma B.V., a Holland-based privately held specialty pharmaceutical company, announced Wednesday a deal in which its for its Alvesco Inhalation Aerosol asthma treatment will be exclusively available at Walgreens Boots Alliance Inc.

Covis Pharma's asthma treatment to be available at Walgreens for free for those with commercial insurance

Boeing

Canada Goose Holdings

These stocks have all fallen in value in the past month and could be attractive buys on the dip.

3 Top Stocks  You Can Buy on Sale: BA, GOOS & WBA

After a lukewarm Q1 2020, shares are nearing value territory.

Why Walgreens Boots Alliance Isn't the Value Stock You're Looking For...Yet

Walgreens Boots Alliance Is A Strong Buy

Walgreens Boots Alliance Inc (NASDAQ: WBA) reported weak operating results for the fiscal first quarter.

Credit Suisse Needs Better Visibility Into Walgreens Earnings Growth

Walgreens Boots Alliance Inc (NASDAQ: WBA) reported its first fiscal quarter earnings on Wednesday, January 8 before the market opened.

Walgreens Isn't Getting Closer To Turning Sickness To Health

Though two partnerships Walgreens has to strengthen the drugstore chain’s relationships with physicians remain in testing stages, company executives say they are performing well and a future expansion could be around the corner.

Walgreens Sees More Doctors Connected To Its Drugstores

FireEye

The winter cold froze out shares of a top pharmacy chain and a cybersecurity specialist.

Why These 2 Stocks Stumbled on Wednesday

Uber

Tanger Factory Outlet Centers

Veeva Systems

Walgreens, Uber, Tanger Outlets and Veeva were our top stock trades for Thursday. Let's look at the charts to see what's happening.

News for Walgreens Stock (WBA)